SSY Group (02005.HK): Labetalol Hydrochloride Has Been Approved by the National Medical Products Administration for Registration as an API for Use in Marketed Formulations

Zhitong Finance APP news, SSY Group (02005.HK) announced that the Group's labetalol hydrochloride has been approved by the National Medical Products Administration of China for registration as an active pharmaceutical ingredient for use in marketed formulations. Labetalol hydrochloride is mainly used for the treatment of hypertension.